Working… Menu

A Study of DA-8159 in Subjects With Erectile Dysfunction

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00282607
Recruitment Status : Completed
First Posted : January 27, 2006
Last Update Posted : February 28, 2007
Information provided by:
Dong-A PharmTech Co., Ltd.

Brief Summary:
The purpose of this study will be to evaluate the clinical efficacy and safety of DA-8159, an orally administered, potent and selective inhibitor of PDE5, versus placebo for the treatment of subjects with erectile dysfunction (ED).

Condition or disease Intervention/treatment Phase
Erectile Dysfunction Drug: DA-8159 Phase 2

Detailed Description:

This will be a multi-center, randomized, double-blind, placebo-controlled, parallel-group study in 300 erectile dysfunction patients. Patients will complete a screening visit (V1) to determine eligibility for the study based on the International Index of Erectile Function (IIEF) erectile function (EF) domain scores, patient history and safety measures. Patients that meet the entrance criteria for this study will enter a 4 week, drug-free run-in period to establish a baseline for the erectile function domain score and to meet the criteria for participation in the study.

Patients successfully completing screen will be randomly assigned to one of four treatment groups at Visit 2 (V2): placebo or one of 3 active drug doses of DA-8159 tablets. Patients will be given medication for at-home use and will also be given diaries for recording information regarding sexual encounters, quality of erections and adverse events. At 4-week intervals for 3 months (V3, V4, V5), patients will return to the clinic to review and collect SEP diaries, safety data, 12-lead ECG and medication reconciliation. In addition, at each 4-week interval patients will complete an IIEF, and at Visit 5 will have blood drawn for safety evaluation.

The primary efficacy end points are: a) the change in score (baseline to Visit 5) for the Erectile Function domain score of the IIEF, b) change in response, relative to baseline, for sexual encounter profile (SEP) question 2, and c) change in response, relative to baseline, for SEP question 3. For DA-8159 tablets to be judged efficacious, the DA-8159 tablet groups must be shown superior to the placebo group on all three measures.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 300 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Randomized, Placebo-Controlled, Double-Blind, Parallel Design Phase 2 Dose Ranging Trial To Assess The Safety and Efficacy of DA-8159 Tablets in Male Subjects With Erectile Dysfunction.
Study Start Date : May 2005
Study Completion Date : June 2006

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. The primary efficacy end points are:
  2. the change in score (baseline to Visit 5) for the Erectile Function domain score of the IIEF;
  3. change in response, relative to baseline, for sexual encounter profile (SEP) question 2, and
  4. change in response, relative to baseline, for SEP question 3.
  5. Safety will be assessed by monitoring adverse events and changes in vital signs, clinical laboratory test results, 12-lead ECG, and physical examinations.

Secondary Outcome Measures :
  1. The study has several secondary efficacy measurements including:
  2. changes in the satisfaction of intercourse, orgasmic function, sexual desire and overall satisfaction domains of the IIEF,
  3. changes from baseline in SEP questions 1, 4 and 5;
  4. the global assessment questionnaire (GAQ), and
  5. changes from baseline in patient self assessment questionnaire (PSAE) scores.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   19 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Is male and at least 19 years of age.
  2. Has a stable monogamous relationship for at least 6 months with a consenting female partner (vaginal intercourse is a required study activity).
  3. Provides written informed consent.
  4. The subject’s female partner provides written informed consent.
  5. Has a history of ED (clinically defined as the inability to attain and maintain an erection of the penis sufficient to permit satisfactory sexual intercourse) of at least 3 months duration. The investigator will record the etiology of the ED (organic, psychogenic or mixed).
  6. Has scored between 6-25 for the Erectile Function domain score (Questions Number 1-5, 15) at both Visits 1 & 2.
  7. Completes least four diary entries by Visit 2, showing at least 4 attempts at sexual intercourse with a 50% or greater failure rate in achieving or in maintaining an erection sufficient to complete intercourse (defined as answering “no” to SEP questions #2 or #3).
  8. The subject’s partner is not pregnant or lactating and both subject and partner agree to the use of a medically acceptable form of birth control. Exceptions would be subjects with a vasectomy or partners that are post menopausal, and partners that have had a tubal ligation or hysterectomy.

Exclusion Criteria:

  1. Has a history of stroke, myocardial infarction, or coronary artery disease within the past 6 months.
  2. Has a history of cardiac failure, angina, or life-threatening arrhythmia within the past 6 months.
  3. Is taking nitrate medication in any form(Appendix 7)
  4. Is taking alpha blockers.
  5. Has a clinically significant abnormal laboratory value as determined by the principal investigator.
  6. Has a history of uncontrolled diabetes (HbA1c>9%).
  7. Has a history of proliferative diabetic retinopathy.
  8. Has a history of spinal cord injury or a radical prostatectomy or radical pelvic surgery.
  9. Has a supine blood pressure lower than 90/50mmHg or uncontrolled hypertension higher than 170/100mmHg.
  10. Has a anatomical deformity of the penis such as severe penile fibrosis or Peyronie’s disease.
  11. Has a thyroid stimulating hormone (TSH) level lower than 30% of LLN.
  12. Has erectile dysfunction caused by neurological or endocrine factors such as hyperprolactinemia or low serum testosterone levels (<300 ng/dl).
  13. Has hepatic impairment (GOT, GPT levels > 3 x ULN).
  14. Has renal impairment (serum creatinine ≥ 2.5mg/dl).
  15. Has a history of hematological disorder such as bleeding disorder or a risk of GI bleeding such as peptic ulceration.
  16. Has a history of retinitis pigmentosa.
  17. Has a history of sickle cell disease, multiple myeloma, leukemia or any other disorders that may cause priapism.
  18. Has a history of significant psychiatric disorder.
  19. Has a history of central nervous system disorders such as stroke, transient ischemic attacks, or spinal cord injury.
  20. Has a history of drug abuse (alcohol, marijuana, cocaine, or opiates).
  21. Has a known sensitivity to drugs especially to phosphodiesterase type 5 inhibitors such as Viagra, Cialis or Levitra.
  22. Has used other erectile dysfunction therapies including nutraceutical and herbal products within 14 days prior to entering into this study.
  23. Is using concomitant medications that are known or suspected to interact with PDE 5 inhibitors such as the following:

    1. Antibacterial: erythromycin
    2. Antifungals: itraconazole, ketoconazole
    3. Antivirals: ritonavir, saquinavir, amprenavir, indinavir, nelfinavir
    4. H2 receptor antagonist: cimetidine
    5. Anticoagulants, androgens, trazodone
  24. Have other sexual disorders such as hypoactive sexual desire.
  25. Have previously failed to respond to PDE-5 inhibitors such as Viagra, Cialis or Levitra.
  26. Have a major illness that in the opinion of the investigator would interfere with the conduct of the study.
  27. Has not participated in a clinical drug study within the last 30 days prior to entering this study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00282607

Layout table for location information
United States, Alabama
Medical Affiliated Research Center
Huntsville, Alabama, United States, 35801
United States, California
The Male Clinic
Beverly Hills, California, United States, 90212
South Orange County
Laguna Woods, California, United States, 92653
California Profession Research
Newport Beach, California, United States, 92660
West Coast Clinical Research
Tarzana, California, United States, 91356
United States, Colorado
Urology Research Options
Aurora, Colorado, United States, 80012
United States, Connecticut
Connecticut Clinical Research Center
Waterbury, Connecticut, United States, 06708
United States, Florida
South Florida Medical Research
Aventura, Florida, United States, 33180
Florida Foundation for Healthcare Research
Ocala, Florida, United States, 34474
United States, Indiana
Northeast Indiana Research, LLC
Fort Wayne, Indiana, United States, 46825
United States, Maryland
Drs. Werner, Murdock & Francis, P.A. , Urology Associates
Greenbelt, Maryland, United States, 20770
United States, New York
Accumed Research Associates
Garden City, New York, United States, 11530
Center for Urologic Research of Western New York
Williamsville, New York, United States, 14221
United States, Rhode Island
University Urological Researcgh Institute
Providence, Rhode Island, United States, 02904
United States, Texas
Urology San Antonio Research
San Antonio, Texas, United States, 78229
Sponsors and Collaborators
Dong-A PharmTech Co., Ltd.
Layout table for investigator information
Study Director: James L Yeager, RPh., Ph.D.
Principal Investigator: Harin Padma-Nathan, MD The Male Clinic

Layout table for additonal information Identifier: NCT00282607     History of Changes
Other Study ID Numbers: DA 2005-001
First Posted: January 27, 2006    Key Record Dates
Last Update Posted: February 28, 2007
Last Verified: February 2007
Keywords provided by Dong-A PharmTech Co., Ltd.:
Erectile Dysfunction
Additional relevant MeSH terms:
Layout table for MeSH terms
Erectile Dysfunction
Sexual Dysfunction, Physiological
Genital Diseases, Male
Sexual Dysfunctions, Psychological
Mental Disorders
Phosphodiesterase 5 Inhibitors
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action